Akari Therapeutics Announces International Clinical Development Program of Nomacopan for the Potential Treatment of COVID-19 Pneumonia

Source - MicroSmallCap

Clinical studies both underway and planned for patients with COVID-19 pneumonia in the U.S., U.K., and Brazil
Proposed multi-center U.S. randomized clinical program in regulatory submission following the treatment of patients via expanded access programs

In Brazil, patient recruitment completed for proof of principle (POP) clinical study; potential progression into follow-on randomized study expected early Q4 2020

Nomacopan selected by AGILE COVID-19 clinical trial initiative in the U.K.

Data from approximately 50 U.K. patients expected early Q4 2020 from an observational study focused on identifying potential therapeutic biomarkers for optimizing use of nomacopan for COVID-19 pneumonia patients ...

Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.

All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email